Pharmacological intravitreal treatment for macular edema in branch retinal vein occlusion: Three-month results | Zendy

Jelena Karadžić | Zendy; Igor Kovačević | Zendy; Jelena Ljikar | Zendy; Z Grgić | Zendy; Gordana Devečerski | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pharmacological intravitreal treatment for macular edema in branch retinal vein occlusion: Three-month results

Author(s) -

Jelena Karadžić,

Igor Kovačević,

Jelena Ljikar,

Z Grgić,

Gordana Devečerski

Publication year - 2015

Publication title -

medicinski pregled

Language(s) - English

Resource type - Journals

eISSN - 1820-7383

pISSN - 0025-8105

DOI - 10.2298/mpns1510295k

Subject(s) - medicine , macular edema , ophthalmology , bevacizumab , visual acuity , branch retinal vein occlusion , retinal vein , triamcinolone acetonide , edema , retinal , central retinal vein occlusion , surgery , chemotherapy

Macular edema is the main cause of visual loss in patients with branch retinal vein occlusion. Macular edema is initially reversible, but over time, permanent loss ofvision occurs from structural damage to the macula. For this reason, there is a need for more rapid and effective treatments than laser photocoagulation which has been established as a gold standard. There are several pharmacologic agents which have changed the management of macular edema.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research